SummaryObjectiveTo report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management.Case ReportsThe patient in the first case developed grade 4 toxicity and had a partial response after the fourth dose of intravenous methylene blue was administered. Full recovery occurred 4 days after the development of IIE. The patient in the second case, who had grade 3 toxicity, had completely recovered 32 hours after the first dose of thiamine.ConclusionCareful evaluation of patients with recurrent gynecologic cancers and vigilance during infusion of chemotherapeutic regimens are important in reducing the risk and timely management of IIE. Both methylene blue and thiamine appear to be effect...
Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neuro...
Chemotherapy may be responsible for central and/or peripheral neurotoxicity. These neurological comp...
We report a phase II study of bleomycin, ifosfamide, and cisplatin (BIP) in cervical cancer. Our aim...
SummaryObjectiveTo report two cases of recurrent uterine sarcoma that developed ifosfamide-induced e...
Ifosfamide, an alkylating agent used in cancer treatments, can cause neurotoxicity. The clinical pre...
Introduction Ifosfamide is an alkylating agent, mostly used against variety of solid tumors in pedia...
Methylene blue is a widely used treatment for ifosfamide neurotoxicity. We present a case of severe ...
Ifosfamide associated central nervous system toxicity has been reported in 5% to 30%of patients trea...
Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopat...
Ifosfamide is an alkylating antineoplastic prodrug used to treat many solid tumors. The metabolism o...
Background/PurposeIfosfamide, a widely used chemotherapeutic agent, has been frequently associated w...
Ifosfamide, a widely used chemotherapeutic agent, has been frequently associated with encephalopathy...
Ifosfamide is an alkylating chemotherapeutic agent that is a structural analog of cyclophosphamide. ...
International audienceBACKGROUND:Several clusters of encephalopathy occurred after the market change...
The clinical use of the alkylating oxazaphosphorine ifosfamide is hampered by a potentially severe e...
Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neuro...
Chemotherapy may be responsible for central and/or peripheral neurotoxicity. These neurological comp...
We report a phase II study of bleomycin, ifosfamide, and cisplatin (BIP) in cervical cancer. Our aim...
SummaryObjectiveTo report two cases of recurrent uterine sarcoma that developed ifosfamide-induced e...
Ifosfamide, an alkylating agent used in cancer treatments, can cause neurotoxicity. The clinical pre...
Introduction Ifosfamide is an alkylating agent, mostly used against variety of solid tumors in pedia...
Methylene blue is a widely used treatment for ifosfamide neurotoxicity. We present a case of severe ...
Ifosfamide associated central nervous system toxicity has been reported in 5% to 30%of patients trea...
Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopat...
Ifosfamide is an alkylating antineoplastic prodrug used to treat many solid tumors. The metabolism o...
Background/PurposeIfosfamide, a widely used chemotherapeutic agent, has been frequently associated w...
Ifosfamide, a widely used chemotherapeutic agent, has been frequently associated with encephalopathy...
Ifosfamide is an alkylating chemotherapeutic agent that is a structural analog of cyclophosphamide. ...
International audienceBACKGROUND:Several clusters of encephalopathy occurred after the market change...
The clinical use of the alkylating oxazaphosphorine ifosfamide is hampered by a potentially severe e...
Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neuro...
Chemotherapy may be responsible for central and/or peripheral neurotoxicity. These neurological comp...
We report a phase II study of bleomycin, ifosfamide, and cisplatin (BIP) in cervical cancer. Our aim...